Wellgistics Health, Inc.

Wellgistics Health, Inc. received an extension from Nasdaq until October 12, 2026, to regain compliance with the $2.5 million stockholders' equity requirement, which was $(12,447,801) as of December 31, 2025. The company is pursuing a merger with DataVault AI and other acquisitions, projecting a post-transaction stockholders' equity of approximately $40 million and a combined asset value of $4 billion. Separately, Nasdaq confirmed that Wellgistics Health has regained compliance with the minimum $1.00 bid price requirement, closing that matter.

Wellgistics Health, Inc. secured $16,906,250 in new funding through a Securities Purchase Agreement, issuing convertible promissory notes with an aggregate principal amount of $21,132,812.50 and warrants to accredited investors. The notes bear 0% interest, mature in 12 months, and are convertible into common stock or Series A Preferred Stock. Additionally, holders of a majority of the company's common shares, totaling 1,333,930 shares, entered into a 90-day lock-up agreement, demonstrating shareholder confidence in the company's growth strategy.

Wellgistics Health, Inc. issued a letter to shareholders outlining its strategic vision for healthcare, emphasizing vertical integration and blockchain technology. The company believes blockchain is crucial for creating a unified data fabric to address healthcare inefficiencies. This strategy is supported by recent transactions, including the formation of DelivMeds AI for tokenized data management, the acquisition of the QOLPOM patent portfolio for patient verification and medical drone IP, and a controlling interest in Tollo Health to directly engage patients.

Wellgistics Health, Inc. entered into a binding term sheet to form DelivMeds AI, Inc., a new healthcare company with an expected combined asset value of $4 billion. This involves acquiring QOLPOM intellectual property from EOS Technology Holdings and Scilex Holding Company, expanding its PharmacyChain license with Datavault AI, and acquiring a controlling interest in Tollo Health, LLC. Additionally, the company announced a 1-for-50 reverse stock split to regain Nasdaq compliance and amended a note purchase agreement, increasing the principal to $1.5 million. Gerald Commissiong was also appointed Interim Co-CEO.

Wellgistics Health, Inc. reported its first quarter 2026 financial results, showing significant sequential revenue growth and a substantial reduction in net operating loss. The company's Q1 2026 revenue reached $0.929 million, with Q2 2026 projected to hit $1.775 million. Strategic initiatives include a joint venture with Kare Pharmtech to expand telepharmacy capabilities and a partnership with Tollo Health for medical foods and AI-driven health tools. Additionally, the company terminated non-binding letters of intent with Neuritek and WellCare to streamline its focus.

Wellgistics Health, Inc. reported a net loss of $7.74 million for the three months ended March 31, 2026, a significant improvement from the $32.43 million loss in the prior year period, but revenues declined sharply to $1.56 million from $10.86 million. The company faces substantial doubt about its ability to continue as a going concern due to its accumulated deficit of $118.77 million and low cash balance. Additionally, Wellgistics received Nasdaq deficiency notices for failing to meet minimum bid price and stockholders' equity requirements, risking delisting. Management is pursuing a reverse stock split, new financing, and a collaboration agreement to address these challenges.

Wellgistics Health, Inc. announced on May 15, 2026, that it will release its financial results for the first quarter of 2026. The company plans to report these results on Tuesday, May 19, 2026, after the market closes.

Wellgistics Health, Inc. announced the withdrawal of its Preliminary Proxy Statement on Schedule 14A, which was initially filed on May 14, 2026. The company decided not to proceed with the preliminary proxy materials in their current form as it continues to evaluate potential strategic transactions. Wellgistics Health may file revised proxy materials at a later date, and no definitive proxy materials were distributed to stockholders.

Wellgistics, LLC, a subsidiary of Wellgistics Health, Inc., entered into a Forbearance Agreement with Marco Capital, Inc. on May 1, 2026, acknowledging an outstanding debt of approximately $1.77 million. Marco Capital agreed to temporarily forbear from exercising its rights and remedies until June 15, 2026. The agreement mandates bi-weekly payments of $50,000 and requires a portion of future financing proceeds to be applied to the debt, which accrues interest at Term SOFR plus 11.5%.

Wellgistics Health, Inc. filed an Amendment No. 1 to its Current Report on Form 8-K to correct the Date of Report and restate Item 1.01. The company entered into an Amended Settlement Agreement with Silverback Capital Corporation on February 9, 2026, which amends a previously disclosed Original Settlement Agreement. This filing clarifies that the Amended Settlement Agreement constitutes the material definitive agreement.